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Abstract In this study we show that phosphorylation of
extracellular signal-regulated kinase (ERK1/2; also known as
p44/42MAPK) following peroxynitrite (ONOO3) exposure
occurs via a MAPK kinase (MEK)-independent but PKC-
dependent pathway in rat-1 fibroblasts. ONOO3-mediated
ERK1/2 phosphorylation was not blocked by MEK inhibitors
PD98059 and U0126. Furthermore, no increase in MEK
phosphorylation was detected upon ONOO3 treatment. Stau-
rosporine was used to investigate whether protein kinase C
(PKC) is involved. This was confirmed by down-regulation of
PKC by phorbol-12,13-dibutyrate, which resulted in significant
reduction of ERK1/2 phosphorylation by ONOO3, implying that
activation of ERK by ONOO3 depends on activation of PKC.
Indeed, PKCK and O were activated upon ONOO3 exposure.
When cells were treated with ONOO3 in a calcium-free buffer,
no activation of PKCK was detected. Concomitantly, a reduction
of ERK1/2 phosphorylation was observed suggesting that
calcium was required for translocation of PKCK and ERK
phosphorylation by ONOO3. Indeed, ONOO3 exposure
resulted in increased cytosolic calcium, which depended on the
presence of extracellular calcium. Finally, data using Go«6976, an
inhibitor of calcium-dependent PKC activation, implied that
ONOO3-mediated ERK1/2 phosphorylation depends on activa-
tion of a calcium-dependent PKC. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Signal transduction pathways respond to a variety of extra-
cellular signals such as mitogenic or environmental stimuli,
and oxidative stress. One such component of the signal trans-
duction pathway is mitogen-activated protein kinase
(MAPK), whose activation or inactivation plays a key role
in transducing extracellular signals into intracellular events
and leads ultimately, to modulation of gene expression. The
MAPK family constitutes three major classes, namely: stress-
activated protein kinases (SAPK or JNK), the p38MAPK and
the extracellular signal-regulated kinases (ERK). While JNK
and p38MAPK mainly respond to environmental stress and
cytokine stimulation, the ERKs serve mainly as signaling mol-
ecules involved in regulation of cell proliferation. In mamma-
lian cells two forms of ERK namely, ERK1 and ERK2 have
been identi¢ed.
There is increasing evidence suggesting that reactive oxygen
species activate or inactivate signaling pathways involving ty-
rosine and serine/threonine kinases and thereby, regulate
phosphorylation of MAPKs. Indeed, MAPKs are reported
to be activated in response to various forms of oxidative stress
such as UV irradiation [1], hydrogen peroxide [2], nitric oxide
[3], and peroxynitrite (ONOO3) [4^7]. Of particular interest is
the highly reactive ONOO3, which is involved in oxidative
damage detected in several pathological conditions such as
in£ammation, ischemia/reperfusion injury, atherosclerosis
and neurological disorders (reviewed in [8,9]). In vivo,
ONOO3 is formed from a di¡usion-limited reaction of nitric
oxide and superoxide. As stated above, ONOO3 activates
MAPK. Recently, Zhang et al. have suggested that activation
of MAPK kinase (MEK) is necessary for MAPK phosphory-
lation in rat lung ¢broblasts [7]. However, the exact mecha-
nism by which ONOO3 induces MAPK phosphorylation re-
mains unclear.
The present work was conducted to investigate the mecha-
nism by which ONOO3 activates ERK1/2 in rat-1 ¢broblasts.
We report in this paper that ONOO3 can activate ERK in-
dependent of MEK activation. Further, for the ¢rst time, we
present evidence that activation of ERK by ONOO3 is de-
pendent on protein kinase C (PKC), most likely, a calcium-
dependent PKC.
2. Materials and methods
2.1. Cells
Rat-1 ¢broblasts [10] were obtained from Hubrecht laboratories,
Utrecht, The Netherlands. The cells were grown in Dulbecco’s modi-
¢ed Eagle’s medium (Gibco, UK) with 10% fetal calf serum (Gibco,
UK) and cultured at 37‡C in a 5% CO2 humidi¢ed atmosphere. The
cells were allowed to grow in 35-mm dishes to a ¢nal density of 60 000
cells/cm2.
2.2. Antibodies
The antibodies against phosphorylated ERK1/2, MEK1/2, and
phosphorylated MEK1/2 were purchased from New England Biolabs,
Beverly, MA, USA. The ERK2 monoclonal antibody was obtained
from Upstate Biotechnologies, Lake Placid, NY, USA. Antibodies
against various PKC isoforms were from Transduction labs, Lexing-
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ton, KY, USA. Horseradish peroxidase-conjugated secondary anti-
bodies were purchased from Jackson Immunoresearch Laboratories
Inc, West Grove, PA, USA.
2.3. ONOO3 treatments
ONOO3 was obtained as a 75 mM stock in 10 mM KOH (stored at
380‡C) and was a gift from Prof. W.H. Koppenol (Laboratorium fu«r
Anorganische Chemie ETHZ, Zurich, Switzerland). Prior to ONOO3
treatment, cells were washed with phosphate-bu¡ered saline (PBSglc)
(140 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4,
pH 7.2 with 0.9 mM CaCl2, 0.5 mM MgCl2 and 5 mM glucose added
freshly on day of use) and incubated in the PBSglc for 10^15 min at
37‡C. In some experiments, CaCl2 was excluded from PBSglc
(PBS3Ca). ONOO3 was added directly to the dishes, using shaking
for 10 s, to a ¢nal concentration of 200 WM (unless otherwise men-
tioned) and subsequently incubated for 2^180 min at 37‡C. To adjust
for the possible e¡ect of a change in pH, controls received equivalent
amounts of 10 mM KOH. A parallel set of plates received decom-
posed ONOO3, to exclude e¡ects of decomposition products. Decom-
posed ONOO3 was prepared by incubating ONOO3 in PBSglc (to a
¢nal concentration of 200 WM) at 37‡C for 3 h.
Following treatment, cells were placed on ice and washed with ice
cold PBSglc and samples prepared for Western blotting.
2.4. MEK inhibitors
Cells were pre-incubated with MEK inhibitors PD98059 (50 WM of
20 mM stock; Calbiochem, La Jolla, CA, USA) for 40 min or U0126
(40 WM of 10 mM stock; Promega, Madison, WI, USA) for 30 min
prior to treatment with ONOO3. The inhibitors were present in the
PBSglc throughout ONOO3 treatment.
2.5. PKC inhibitors/down-regulators
PKC inhibitors and down-regulators were from Calbiochem, La
Jolla, CA, USA. Staurosporine was added to cells for 15 min prior
to and during treatment with ONOO3 at a ¢nal concentration of
1 WM. Down-regulation of PKC was obtained by pre-incubating cells
for 24 h with 200 nM phorbol-12,13-dibutyrate (PDBU; 200 WM
stock in sterile distilled water). To activate PKC cells were incubated
for 10 min with 200 nM PDBU. At short incubation times PDBU
activates all PKC (except atypical PKC). Go«6976, a speci¢c inhibitor
of calcium-dependent PKC was added to the cells for 40 min before
ONOO3 exposure.
2.6. Cell fractionation
The plasma membrane-enriched fraction of cells was separated
from cytosol using centrifugation as described by Evans, [11] with
minor modi¢cations. Brie£y, following treatment with ONOO3 or
PDBU, cells were scraped on ice in homogenization bu¡er (250 mM
Sucrose, 10 mM Tris^HCl pH 7.4, 1 mM EDTA, 1 mM PMSF, 1 mM
benzamidine, 1 mM sodium orthovanadate, 10 mM sodium £uoride,
1 Wg/ml aprotinin and 5 Wg/ml leupeptin). Cells were homogenized by
passing 20 times through a 24-G syringe. Whole cells and nuclei were
removed by centrifuging for 5 min at 1000Ug, 4‡C. The supernatant
was subsequently centrifuged for 15 min at 10 000Ug, 4‡C. The super-
natant was considered as cytosolic fraction. The pellet (plasma mem-
brane-enriched fraction) washed twice with homogenization bu¡er.
The protein content of each of the fractions was determined using
the BCA protein assay kit (Pierce, Rockford, IL, USA) as per the
manufacturer’s instructions. Samples were then prepared for Western
blotting.
2.7. Preparation of samples and Western blotting
Following treatment, the rat-1 cells or cell fractions were taken up
in sample bu¡er (8.3% glycerol, 75 mM dithiothreitol, 1.7% sodium
dodecyl sulfate, 0.0025% bromophenol blue and 20 mM Tris^HCl pH
8.8), boiled for 10 min and stored at 320‡C until use. Proteins (20^25
Wg) were separated by SDS^PAGE on a 10% polyacrylamide gel and
blotted on to PVDF membranes. The blots were blocked overnight at
4‡C using 2% milk powder (Protifar, Nutricia, The Netherlands) in
PBS^Tween (0.05% v/v Tween-20 in PBS). Following incubation with
primary antibodies (diluted in 0.5% milk powder in PBS^Tween) for
60 min at room temperature, the blots were washed for 40 min and
incubated for 45 min with secondary horseradish peroxidase-coupled
antibodies (diluted in the 0.5% milk powder). After washing for
30 min, the proteins of interest were detected using a chemilumines-
cence detection kit (Life Sciences Products, Boston, MA, USA).
2.8. Measurement of calcium
Cytosolic calcium in cells was measured using the £uorescent dye
INDO-1 AM (Molecular Probes Inc., Eugene, OR, USA). Cells were
seeded on 25-mm coverslips to a density of 60 000 cells/cm2. Cells
were washed with PBSglc or PBS3Ca coverslips were transferred to a
dish containing 5 Wg INDO-1 AM/ml PBSglc or PBS3Ca and incu-
bated for further 30 min, protected from light. The intensity of
INDO-1 bound to calcium was observed using a confocal scanning
laser microscope (Nikon RCM8000 connected to a Nikon Diaphot
300 inverted microscope; Objective water immersion 40U, NA1.15
excitation V351 nm; emission PMT1V400 nm; emission
PMT2V490 nm). Results presented are a ratio of emission 1 and
emission 2 using ‘false colors’ to visualize changes in £uorescence
intensities. Changes in calcium levels were recorded continuously for
up to 10 min after ONOO3 exposure.
All results presented are a fair representation of results obtained
from at least three independent experiments.
3. Results
3.1. ONOO3 activates ERK1/2
Incubation of cells with 50 WM or more of ONOO3 for 10
min resulted in increased ERK phosphorylation (Fig. 1A).
The activation was also time-dependent (Fig. 1B; panel 1).
Maximum phosphorylation was observed between 10 and 30
min after ONOO3 supplementation followed by a transient
decrease in ERK phosphorylation. Further, treatment with
decomposed ONOO3 did not a¡ect the phosphorylation of
MAPK indicating that the observed activation is not the e¡ect
of a degraded product of ONOO3 (data not shown).
3.2. ERK1/2 phosphorylation by ONOO3 occurs via a
MEK-independent pathway
Inhibitors of MEK (PD98059 and U0126) were used to
investigate if ONOO3 activated ERK via MEK. PD98059
exerts its inhibitory e¡ects by binding directly to the inactive
(non-phosphorylated) form of MEK after blocking its activa-
tion by Raf [12,13]. U0126 on the other hand, does not a¡ect
MEK phosphorylation but directly inhibits activation of
MAPK by MEK1 [13,14].
Cells were incubated with the inhibitors and were subse-
quently, treated with 200 WM ONOO3 for 2^30 min at
37‡C. Incubation of rat-1 cells with ONOO3 alone resulted
in maximum phosphorylation of ERK1/2 at 10^30 min (Fig.
1B; panel 1). Surprisingly, both inhibitors did not block ERK
activation by ONOO3 (Fig. 1B; panels 2 and 3) implying that
MEK activation is not required for ERK phosphorylation by
ONOO3. In contrast, both inhibitors completely blocked
ERK phosphorylation in serum-deprived cells incubated
with complete medium for 10 min (used as positive control;
data not shown) indicating that serum activation of ERK
occurs via the MEK pathway. This result also con¢rmed the
e¡ectiveness of both the inhibitors in blocking activation of
ERK via MEK.
MEK-independent ERK1/2 phosphorylation was further
veri¢ed by detecting phosphorylated MEK in cells following
ONOO3 treatment (Fig. 1C). Incubating cells with ONOO3
for 2^30 min did not signi¢cantly increase MEK phosphory-
lation. On the other hand, serum-starved cells incubated for
10 min in complete medium exhibited elevated MEK1/2 phos-
phorylation (data not shown). This result con¢rms that in-
deed, ERK phosphorylation in rat-1 cells by ONOO3 occurs
via a MEK-independent pathway, in contrast to the MEK-
dependent, MAPK activation by serum.
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3.3. E¡ect of PKC inhibition/down-regulation
To elucidate the mechanism by which ERK1/2 is activated
by ONOO3, PKC inhibitors and down-regulators were used.
Panel 4 of Fig. 1B shows the e¡ect of staurosporine, an
inhibitor of PKC activity, on ONOO3-induced phosphoryla-
tion of MAPK. Pre-incubation of cells with Staurosporine
resulted in a signi¢cant inhibition of ONOO3 activation of
ERK (compare panels 1 and 4) suggesting that in rat-1 ¢bro-
blasts, ONOO3 activates MAPK via a PKC-dependent path-
way. Furthermore, ERK phosphorylation on serum activation
was not a¡ected by staurosporine suggesting once again, that
di¡erent pathways are involved in the activation of ERK by
serum and ONOO3 (data not shown).
To validate the role of PKC in ONOO3 activation of ERK,
we down-regulated PKC in the cells by incubating them with
PDBU for 24 h. The PKC down-regulated cells were treated
with ONOO3 and subsequently, PKCK and phosphorylated
ERK detected. The results are presented in Fig. 2. A complete
down-regulation of PKCK protein, being one of the PKC iso-
forms known to be down-regulated by PDBU, was indeed
observed in all cell samples incubated with PDBU (Fig. 2;
top panel). Interestingly, PDBU-treated cells exhibited signi¢-
cant reduction in ERK1/2 phosphorylation (Fig. 2; middle
panel). These results support and give more speci¢c evidence
for our proposition that PKC is involved in ONOO3-induced
MAPK activation.
3.4. ONOO3 translocates PKC to the membrane
The results using PKC inhibition/down-regulation clearly
indicate that activation of PKC is involved in the phosphor-
ylation of ERK by ONOO3. PKC is known to translocate to
the plasma membrane upon activation. Therefore, plasma
membrane and cytosol fractions of rat-1 cells were separated
after exposure to ONOO3 and total PKC protein detected in
the fractions. To date 12 di¡erent PKC isoforms have been
identi¢ed in mammalian cells. The isoforms K, O, N, V, and j
could be identi¢ed in rat-1 ¢broblasts (data not shown; West-
ern blot on total cell lysates using speci¢c antibodies directed
against the various PKC isoforms). In order to identify which
of these isoforms were activated by ONOO3, membrane and
cytosolic fractions of the cells were probed with antibodies
directed against each of these isoforms. We found only
PKCK and O to be activated upon ONOO3 treatment (Fig.
3A,B, respectively). As expected, PDBU substantially acti-
vated PKCK and PKCO. Exposure of cells to ONOO3 re-
sulted in a reduction of PKCK in the cytosol fraction concom-
itant with a marked increase (V2.4-fold; measured using
densitometry) in membrane-bound PKCK (Fig. 3A). Simi-
larly, a s 2-fold increase in membrane-associated PKCO was
also observed (Fig. 3B). PKCK belongs to the conventional
PKC group and is therefore, dependent on calcium for its
activation. On the other hand, PKCO is a novel PKC and is
not dependent on calcium for its activation. In order to de-
termine the PKC isoform that might be involved in ERK1/2
phosphorylation, we studied the role of calcium in PKC and
ERK activation by ONOO3.
Fig. 1. ONOO3 exposure results in phosphorylation of ERK1/2 via
a MEK-independent but PKC-dependent pathway. A: Cells were in-
cubated with 25^500 WM ONOO3 for 10 min. Controls (C) were in-
cubated with an equivalent amount of 10 mM KOH. B: Detection
of phosphorylated ERK1/2 in cells exposed to 200 WM ONOO3 for
2^30 min (Panel 1). Panels 2 and 3 present data on ONOO3-in-
duced ERK1/2 activation when cells are pre-treated with MEK in-
hibitors PD98059 and U0126, respectively. The e¡ect of PKC inhib-
itor staurosporine on phosphorylation of ERK1/2 by ONOO3 is
depicted in panel 4. ERK2 is presented as a loading control (panel
5) and is a fair representation of the proteins loaded on to each
lane. C: Phosphorylation of MEK following treatment of cells with
200 WM ONOO3 for 2^30 min. For this experiment anti-MEK was
used as a loading control. Control cells (C) received no ONOO3.
Fig. 2. PKC down-regulation with PDBU results in an inhibition of
ERK1/2 activation by ONOO3. Detection of PKCK (top panel) or
phosphorylated ERK1/2 (middle panel) in cells incubated overnight
with (lanes 6^10) or without (lanes 1^5) 200 nM PDBU. Subse-
quently, cells were washed with PBSglc and exposed to 200 WM
ONOO3 for 2^60 min. Anti-ERK2 was used to check protein load-
ing (bottom panel). Controls (C) were not treated with ONOO3.
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3.5. The role of calcium
There have been reports that ONOO3 supplementation re-
sults in increased cytosolic calcium [15]. An increase in cyto-
plasmic calcium can occur via an in£ux of extracellular cal-
cium following ONOO3 exposure. Such an increase in
cytosolic calcium might result in activation of Ca2-dependent
PKC and subsequent phosphorylation of ERK. In order to
test this hypothesis we treated cells with ONOO3 in PBS3Ca.
The level of intracellular calcium after ONOO3 treatment in
PBSglc or PBS3Ca was visualized by loading the cells with
INDO-1 AM. The results are presented in Fig. 4. Within
2 min of treatment with ONOO3 in PBSglc a signi¢cant rise
in cytosolic calcium was observed (Fig. 4A). The calcium lev-
els remained elevated throughout the 10 min tested. In con-
trast, the calcium levels did not change when the cells were
exposed to ONOO3 in PBS3Ca (Fig. 4B). These results clearly
show that treatment of rat-1 ¢broblasts with ONOO3 results
in an increase in cytosolic calcium. Further, the results suggest
that an in£ux of calcium from the extracellular medium is
responsible for the rise in cytosolic calcium after ONOO3
incubation in PBSglc.
To determine whether such increases in calcium levels co-
incide with, and might play a role in the activation of PKC by
ONOO3, we studied the translocation of PKCK (the only
calcium-dependent PKC detected in rat-1 ¢broblasts) to the
membrane following ONOO3 treatment in PBSglc or PBS3Ca
(Fig. 5A). When rat-1 ¢broblasts were exposed to ONOO3 in
PBSglc containing calcium an increase in the amount of PKCK
protein was detected in the membrane fraction. In contrast,
when the cells were treated with ONOO3 in PBS3Ca, no
translocation of PKCK occurred indicating that an in£ux of
extracellular calcium was indeed, required for activation of
PKCK by ONOO3. As a control for PKC translocation
some cells were treated with PDBU for 10 min (Fig. 5A). A
substantial translocation of PKCK was observed when the
cells were stimulated with PDBU in PBSglc as well as in
PBS3Ca. This indicates, as expected, that upon PDBU stim-
ulation PKCK translocates to the plasma membrane inde-
pendent of the calcium level in cells.
Since our results with PKC inhibition/down-regulation also
suggested that PKC activation was involved in ERK phos-
phorylation by ONOO3, we investigated whether extracellular
calcium in£uenced ERK1/2 phosphorylation by ONOO3.
Rat-1 ¢broblasts were exposed to ONOO3 in PBSglc or in
PBS3Ca. The results are presented in Fig. 5B. We observed
Fig. 3. ONOO3 treatment results in PKC translocation to the plas-
ma membrane. Detection of (A) PKCK or (B) PKCO in cytosol
(lanes 1^3) or membrane (lanes 4^6) fractions of rat-1 ¢broblasts.
Cells were incubated with 200 nM PDBU (P) or 200 WM ONOO3
(N) or left untreated (C) for 10 min in PBSglc. After fractionation
equal amounts of protein (20 Wg) were loaded on the gel.
Fig. 4. ONOO3 exposure in PBSglc results in increased cytosolic calcium. Cells were loaded with INDO-1 AM for 30 min before they were
treated with 200 WM ONOO3 for 2 or 10 min in (A) PBSglc or (B) PBS3Ca. Calcium in cells was observed using confocal scanning laser mi-
croscopy. The color bar is a measure of the ratio of bound INDO-1/unbound INDO-1 indicating increasing calcium concentration in cells.
Controls indicate the calcium measured in the cells before ONOO3 exposure.
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that ERK phosphorylation after ONOO3 incubation was sig-
ni¢cantly diminished in cells that had been incubated in
PBS3Ca as compared to those treated in PBSglc (Fig. 5B;
compare panel 2 with panel 1). The results show that extra-
cellular calcium is involved, at least partly, in the activation of
ERK by ONOO3.
Since calcium levels were also involved in the activation of
PKCK by ONOO3 we hypothesized that the phosphorylation
of ERK by ONOO3 may require the activation of a calcium-
dependent PKC. To ¢nd evidence for this hypothesis, a selec-
tive inhibitor of Ca2-dependent PKC, Go«6976, was em-
ployed. Rat-1 ¢broblasts were incubated with 10 WM
Go«6976 for 30 min prior to treatment with ONOO3. The
inhibitor was present throughout ONOO3 exposure. Treat-
ment of cells with ONOO3 in the absence of the inhibitor
resulted in a transient increase in ERK phosphorylation
(Fig. 5B; panel 1). In contrast, a marked reduction in ERK
phosphorylation was observed in cells that had been incu-
bated with Go«6976 prior to treatment with ONOO3 (Fig.
5B; compare panel 3 with panel 1). The result suggests in-
volvement of a Ca2-dependent PKC in ERK1/2 activation by
ONOO3.
4. Discussion
The present results show that ONOO3 induces the phos-
phorylation of ERK1/2 in rat-1 ¢broblasts. For the ¢rst time,
to our knowledge, it is reported that in rat-1 ¢broblasts, the
activation of ERK by ONOO3 occurs via a MEK-independ-
ent, but PKC- and calcium-dependent pathway. Further, we
present evidence that a Ca2-dependent PKC might be in-
volved in ERK phosphorylation by ONOO3.
Phosphorylation of ERK1/2 following ONOO3 exposure
has been previously demonstrated by other researchers [4^7].
These studies have reported that maximum activation of
ERK1/2 by ONOO3 occurred at approximately 15 min of
ONOO3 exposure. Our results indicate that phosphorylation
of ERK1/2 after ONOO3 treatment is highest at 10^30 min
and is therefore, in agreement with the ¢ndings of others.
In order to investigate if ERK1/2 is activated via the Raf^
MEK^MAPK pathway we employed two MEK inhibitors
namely, PD98059 and U0126. Both these inhibitors failed to
inhibit phosphorylation of ERK suggesting that ONOO3-
mediated MAPK activation occurs independent of MEK.
This hypothesis was strengthened by the observation that no
signi¢cant phosphorylation of MEK occurred upon ONOO3
exposure. Jope et al. [6] recently showed that in PC12 cells,
ERK1/2 activation by ONOO3 is mediated via the epidermal
growth factor (EGF) receptor. On the other hand, in a sepa-
rate study, Zhang et al. [7] have reported that ONOO3-medi-
ated phosphorylation of ERK1/2 in rat lung ¢broblasts occurs
independent of EGF receptor (EGFR) or Raf-1 but is depen-
dent on MEK activation. In contrast to the ¢ndings of these
researchers, we have observed that in rat-1 ¢broblasts, MEK
phosphorylation is not required for ERK1/2 activation by
ONOO3. Thus, while these groups observed ERK activation
15 min after ONOO3 exposure, there are di¡erences regard-
ing the proposed mechanisms. This disparity might be attrib-
uted to di¡erences in cell type, concentrations of ONOO3,
mode of administration etc.
In rat-1 ¢broblasts we observed that the PKC inhibitor
staurosporine, signi¢cantly blocked ONOO3-induced ERK1/
2 phosphorylation. This observation implies that the activa-
tion of ERK by ONOO3 depends on PKC. PDBU down-
regulation of PKC resulted in substantial inhibition of
ONOO3-mediated ERK phosphorylation providing further
evidence that PKC activation is required for ERK1/2 activa-
tion in response to ONOO3.
The MEK inhibitor U0126 failed to block ONOO3-induced
ERK1/2 activation. U0126 directly inhibits activated MEK1
and prevents endogenously active MEK1/2 from phosphory-
lating and activating ERK1/2 [13,14]. Therefore, the inability
of U0126 to block the e¡ect of ONOO3 suggests that PKC
can activate ERK1/2 independent of MEK activation. Fur-
thermore, the lack of MEK phosphorylation upon ONOO3
stimulation also points to a MEK-independent pathway for
ERK activation. MEK-independent ERK1/2 activation by
PKC has also been reported by other researchers [16]. PKC
is a multigene family comprising at least 12 distinct isoforms
and is a pivotal constituent of a cascade of biochemical events
that can be triggered by mitogens through cell surface recep-
tors. Oxidative stress such as hydrogen peroxide has been
reported to activate PKC [17,18]. We ¢nd that ONOO3 ex-
posure speci¢cally activates PKCK and O as demonstrated by
their translocation to the plasma membrane. It is possible that
ONOO3 stimulates cell surface receptors initiating a signal
transduction pathway involving PKC and leading ultimately,
to phosphorylation of ERK1/2.
PKCK and O belong to di¡erent classes of PKC isoforms.
PKCK is a conventional PKC and is dependent on calcium for
Fig. 5. Phosphorylation of ERK1/2 by ONOO3 involves a calcium-
dependent PKC. A: Detection of PKCK in cytosol or membrane
fraction of cells treated with 200 nM PDBU (P) or 200 WM
ONOO3 (N) or left untreated (C) for 10 min in PBSglc (lanes 1^3)
or PBS3Ca (lanes 4^6). After cell fractionation equal amounts of
protein (20 Wg) were loaded on gel. B: Cells were treated with 200
WM ONOO3 for 2^60 min or left untreated (C; 10 min) in PBSglc
(panel 1), PBS3Ca (panel 2) and phosphorylated ERK was detected.
In panel 3 cells were pre-treated for 30 min with PKC inhibitor
Go«6976 prior to 200 WM ONOO3 exposure. Controls (C) were left
untreated for 10 min. ERK2 was used as the loading control (panel
4).
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its activation. On the other hand, activation of PKCO (a novel
PKC) is not dependent on calcium. To determine which PKC
isoform might play a role in ERK1/2 phosphorylation by
ONOO3 we investigated the role of calcium in the activation
of PKC and ERK. Exposure of cells to ONOO3 led to a
substantial rise in intracellular calcium levels. Increased cyto-
solic calcium resulting in calcium overload following ONOO3
exposure has also been reported by other researchers [15,19].
Such an increase could occur through enhanced in£ux of
extracellular calcium and/or increased e¥ux from endogenous
calcium stores. We observed that in the absence of calcium in
the bu¡er, ONOO3 caused no change in calcium levels sug-
gesting that treatment of cells with ONOO3 resulted in in£ux
of extracellular calcium rather than an e¥ux of calcium from
cellular stores.
Elevated intracellular calcium levels have been reported to
be capable of activating ERK1/2 in B- and T-lymphocytes
[20,21]. We hypothesized similarly, that in the rat-1 ¢bro-
blasts, exposure to ONOO3 might elevate levels of intracel-
lular calcium leading to activation of ERK via PKC. Indeed,
we found that extracellular calcium was required for
ONOO3-induced translocation of PKCK. Thus, when cells
were treated with ONOO3 in PBS3Ca (calcium-de¢cient
PBSglc), PKCK did not translocate to the plasma membrane.
Interestingly, when the cells were treated with ONOO3 in the
absence of calcium (PBS3Ca), the activation of ERK was also
markedly reduced. This result demonstrates a clear link be-
tween rise in cellular calcium levels, translocation of PKCK
and phosphorylation of ERK following ONOO3 exposure.
Further evidence for involvement of a calcium-dependent
PKC in ERK phosphorylation was obtained when we ob-
served that pre-incubating cells with Go«6976 (a speci¢c inhib-
itor of Ca2-dependent PKC) signi¢cantly diminished ERK1/
2 activation by ONOO3. This con¢rms that ONOO3-medi-
ated phosphorylation of ERK depends on PKC and further-
more, it implies that a Ca2-dependent PKC such as K, L or Q
might be involved. However, PKCK was the only calcium-
dependent PKC detected in rat-1 ¢broblasts. Therefore, our
results suggest a role for PKCK in ONOO3-induced ERK
phosphorylation in these cells. Clearly, additional investiga-
tions are necessary to determine the PKC isoform involved in
ERK phosphorylation by ONOO3.
In summary, the present results provide evidence for in-
volvement of a calcium- and PKC-dependent pathway in the
activation of ERK by ONOO3 in rat-1 ¢broblasts. To our
knowledge, this is also the ¢rst report demonstrating the
translocation of PKC upon ONOO3 stimulation. We hy-
pothesize that exposure of rat-1 ¢broblasts to ONOO3 results
in a rise in calcium levels and an activation of PKC which
ultimately results in ERK1/2 phosphorylation in a MEK-in-
dependent manner. Whether the translocation of PKC by
ONOO3 occurs directly or involves the activation of phos-
pholipase C and subsequent generation of diacylglycerol is not
known and needs to be investigated.
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